Merriman Curhan Ford
-
Notable Analyst Rating Changes 1/19: EVVV, CIEN, JDSU, X Upgraded; IMAX, PAET, JASO, AKS Downgraded
-
Biogen (BIIB) Must Raise Offer for Facet (FACT) to At Least $22/Share -Merriman
-
Merriman Curhan Pounds The Table On Facet Biotechnology (FACT) After Board Formally Rejects Biogen Offer
-
Notable Analyst Rating Changes 7/14: BK, UL, VMW, CNK, NILE Upgraded; MNKD, MAS, BKC, VOD Downgraded
